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Kansas City, KS 66160, USA. Fax: +1 913 588 4701.Expression of BRMS1 causes dramatic suppression of metastasis in multiple in vivo model systems.
As we gain further insight into the biochemical mechanisms of BRMS1, we appreciate the impor-
tance of both molecular and cellular context for functional metastasis suppression. BRMS1 associ-
ates with large chromatin remodeling complexes including SIN3:HDAC which are powerful
epigenetic regulators of gene expression. Additionally, BRMS1 inhibits the activity of NFjB, a
well-known transcription factor that plays signiﬁcant roles in tumor progression. Moreover, BRMS1
coordinately regulates the expression of metastasis-associated microRNA known as metastamir.
How these biochemical mechanisms and biological pathways are linked, either directly or indirectly,
and the inﬂuence of molecular and cellular context, are critical considerations for the discovery of
novel therapeutic targets for the most deadly aspect of tumor progression-metastasis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
BRMS1 (BReast cancer Metastasis Suppressor 1) was ﬁrst de-
scribed in 2000 as a gene that suppressed metastasis without pre-
venting primary tumor growth [1]. The discovery of BRMS1 was
accomplished using a combination of techniques that began with
prior karyotypic observations showing that long and short arms
of chromosome 11 are often sites of ampliﬁcation/deletion and
are associated with the progression of breast cancer [2]. Phillips
and colleagues hypothesized that transferring an intact copy of
neomycin-tagged chromosome 11 into metastatic breast cancer
cells (MDA-MB-435; neo11/435 with introduced chromosome
11) would alter metastatic potential [3]. Using the technique of
microcell-mediated chromosomal transfer (MMCT), they found
signiﬁcantly fewer metastases in the neo11/435 compared to
parental cells with no signiﬁcant changes in orthotopic tumor inci-
dence/growth. Following these experiments, Seraj et al. used dif-
ferential display RT–PCR (DD-RTPCR) to identify transcripts with
P5-fold higher expression in the neo11/435 [1]. One of these tran-
scripts was sequenced, cloned, and transfected into MDA-MB-435
and MDA-MB-231 metastatic breast cancer cells. When injected
into mammary fat pads of athymic mice, BRMS1-transfectedchemical Societies. Published by E
Pathology, 1670 University
x: +1 205 975 1126.
), DWelch@kumc.edu (D.R.
inbow Blvd., Robinson 4030,MDA-MB-435 (435-BRMS1) cells demonstrated decreased inci-
dence and number of metastases to lung and lymph nodes. Ortho-
topic tumor growth rates were similar to parental controls albeit a
lag in growth in the 435-BRMS1 cells for approximately 1 week.
MDA-MB-231 human breast cancer cells expressing BRMS1 (231-
BRMS1) showed a signiﬁcant expression-dependent decrease in
metastatic potential when cells were injected into the lateral tail
veins of athymic mice. These cells were still capable of forming
tumors in the mammary fat pads with similar growth rates as
the parent controls. These results demonstrated that BRMS1 sup-
presses metastasis without blocking tumorigenicity, satisfying
the functional deﬁnition of a metastasis suppressor gene.
Since then, many labs using different model systems showed
BRMS1 to be a metastasis suppressor for breast carcinoma, mela-
noma, ovarian carcinoma, and non-small cell lung carcinoma
(reviewed in [4]). Although not formally demonstrated to suppress
bladder cancer, Seraj et al. found reduced BRMS1 mRNA in a highly
metastatic variant of a human bladder carcinoma cell line T24T
compared to the less metastatic parental line T24 [5]. This pattern
of expression was also noted for one other metastasis suppressor,
RhoGDI2. Robertson et al. suggested the presence of a tumor
suppressor on the long arm of chromosome 11 in human melano-
mas and BRMS1 was subsequently shown to be a bona ﬁde mela-
noma metastasis suppressor gene [6,7]. Quantitative real-time
RT–PCR revealed that BRMS1 mRNA expression is high in melano-
cytes, reduced in early stage melanoma-derived cell lines, and
barely detectable in advanced or metastatic melanoma cell lines.
Introducing BRMS1 into the highly metastatic melanoma cell linelsevier B.V. All rights reserved.
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experimental assays without preventing orthotopic tumor growth.
Similar ﬁndings were noted for models of ovarian carcinoma [8]
and NSCLC [9].
The BRMS1 gene maps to 11q13.1–13.2 [1]. This is within a re-
gion that is often lost in late stage breast cancers and is near sites
that are among the most common ampliﬁcations and deletions
associated with breast cancer progression [2]. Within the 50 up-
stream region there are several putative regulatory elements
including GATA-1, CREB, GATA-2, and CdxA. There is no TATA
box suggesting that transcription of BRMS1 proceeds in a TATA-
independent mechanism [1]. Two putative CpG islands were iden-
tiﬁed in the promoter region of BRMS1 (3477 to 2214 and 531
to +608) and using methylation speciﬁc PCR it was determined the
distal CpG island (3477 to 2214) was methylated in tumori-
genic and metastatic cell lines leading to the suppression of BRMS1
expression [10].
In addition to the wild-type transcript, the mRNA for several
splice variants was identiﬁed. Wild-type BRMS1 has 10 exons span-
ning 741 nucleotides. BRMS1.v2 contains an alternative splice site
in exon 10, BRMS1.v3 has an alternative splice site in exon 5, lacks
exons 6–9, and alternatively splices exon 10, and BRMS1.v4 lacks
exon 9 [11]. These splice variants are differentially expressed in
metastatic compared to non-metastatic breast cancer cell lines.
However, the functional relevance of each variant is presently un-
known since translation to protein has not yet been veriﬁed.
The BRMS1 protein is 246 amino acids and is predicted to be
28.5 kDa [1]; however, it migrates closer to 35 kDa on SDS–PAGE
[11]. This is presumably due to the highly charged N-terminal glu-
tamate rich region within the ﬁrst 50 amino acids. There are two
coiled-coil regions between AA51-81 and AA147-180 and two pre-
dicted nuclear localization sequences between AA198-205 and
AA239-245. The ﬁrst NLS is required for localization to the nucleus
[12,13]. It is not yet clear if the second NLS has any functional rel-
evance to localization and/or trafﬁcking although we have preli-
minary data suggesting roles in nuclear retention (D.R. Hurst and
D.R. Welch, unpublished). Several putative phosphorylation sites
exist however there have been no reports of phosphorylation.
Other members of the SIN3 complex including BRMS1 family
members have been shown to be phosphorylated by cell cycle reg-
ulatory kinases [14,15]. However, whether BRMS1 phosphoryla-
tion occurs and whether the modiﬁcations by cell cycle
machinery are responsible for, or a consequence of, different
growth in orthotopic versus ectopic tissues remains to be deter-
mined. There are no predicted glycosylation sites. The protein is
stabilized by HSP90 and turnover is proteasome dependent [16].
BRMS1 is part of a family that includes suppressor of defective
silencing 3 (SUDS3 or mSds3) and BRMS1-like (BRMS1L or p40)
[17,18]. A conserved region known as the Sds3-like domain is pres-
ent in each of these proteins. This region has not yet been function-
ally deﬁned although it is likely important for protein–protein
interactions. BRMS1 is 23% identical and 49% similar in amino acid
sequence to SUDS3 and 57% identical and 79% similar to BRMS1L.
Expression of SUDS3 in metastatic breast cancer cell lines does
not signiﬁcantly suppress metastasis as would be predicted, sug-
gesting that, although similar, these proteins have distinct func-
tions and do not functionally compensate for one another [17].
High sequence homology at both the DNA and amino acid levels
of BRMS1 is found in multiple species. In particular, the murine
ortholog (Brms1) is 85% homologous at the DNA level and the ami-
no acid sequence is 95% identical [19]. In related subpopulations of
tumor cells derived from a single mammary carcinoma, but vary-
ing in metastatic potential, Brms1 expression was inversely
correlated with increased aggressiveness. Importantly, Brms1
functions as a metastasis suppressor in murine mammary
carcinomas. Upon transfection of Brms1 into 66c14 or 4T1,metastasis was signiﬁcantly suppressed while orthotopic tumor
growth was indistinguishable from parental or vector-only trans-
fectants [19,20]. Interaction with HDAC1 was demonstrated by
co-immunoprecipitation suggesting an association with similar
chromatin remodeling complexes. Altogether, these results suggest
that the mouse ortholog has similar functionalities as human
BRMS1. Interestingly, a genetic mapping study showed that meta-
static ability of mammary tumors using inbred mouse strains was
linked to allelic variations of Brms1 [21,22]. Recent, as yet unpub-
lished data from our laboratories shows that transgenic expression
of Brms1 in F1 generation MMTV-PyMT crosses yields signiﬁcantly
reduced lung metastases while not affecting primary tumor devel-
opment (L.M. Cook, D.R. Hurst, and D.R. Welch, in preparation).
Although it has been clearly demonstrated that BRMS1 sup-
presses metastasis, determining speciﬁc functions and delineating
mechanisms of suppression have proven to be difﬁcult. BRMS1
does not completely block any single step in the metastatic cas-
cade. Rather, it inhibits several hallmarks of metastasis leading to
80–90% inhibition in mouse models of metastasis. Proteomic and
gene array studies have identiﬁed multiple changes in protein cod-
ing and non-coding genes when BRMS1 is expressed [23–26].
These expression changes may be responsible for driving the mul-
tiple phenotypic changes observed including invasion and migra-
tion, restoration of gap junctional intercellular communication
(GJIC), and anoikis. Two mechanisms have been identiﬁed that
could lead to gene expression changes that may be linked includ-
ing interaction with chromatin remodeling complexes and inhibi-
tion of NFjB activity. These are discussed in greater detail below.2. Regulation of gene expression. . .but not a transcription factor
The coordinate expression of genetic programs is necessary to
enable a cancer cell to complete all the required steps of the
metastatic cascade [27–29]. Molecules that regulate gene tran-
scription could dramatically impact the metastatic process. There
have been multiple reports showing that BRMS1 alters the
expression level of metastasis associated genes. The questions
that have not yet been fully answered are how? and which are
the most relevant complexes? There is no evidence for BRMS1
functioning as a transcription factor. However, there is concrete
evidence that it associates with transcriptional repressive chro-
matin remodeling complexes. BRMS1 presumably regulates the
transcription of genes by interaction with large SIN3:HDAC chro-
matin remodeling complexes through the direct interaction with
AT rich interacting domain 4A (ARID4A) and SUDS3 leading to
the suppression of basal transcription [30,31]. These ﬁndings
have been conﬁrmed by protein–protein interaction studies of
other proteins known to be a part of these complexes in addition
to BRMS1 [18,32–36].
Chromatin remodeling complexes are diverse and incompletely
characterized. Much more is known regarding lower species and,
although there are many similarities with the complexes in mam-
mals, they are much more complex and exist in many forms com-
pared to yeast or lower organisms. For example, in Saccharomyces
cerevisiae, two distinct SIN3 complexes have been isolated known
as Rpd3L and Rpd3S (note: a yeast ortholog of BRMS1 has not been
identiﬁed) [37]. However, we and others have demonstrated that
SIN3 complexes in mammalian cells exist in many sizes and are
not limited to only two. The mammalian core components have
been detected in multiple size exclusion FPLC fractions from cell
lysates in sizes ranging from several hundred kDa to those exceed-
ing 2 MDa. Because these components are found in a range of sizes
demonstrates the existence of multiple complexes. Understanding
the composition of these differently sized complexes will be
important to determine how they function.
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sive roles in cancer. Typical studies have been done by ectopically
expressing one gene and characterizing the nature of tumor inhibi-
tion. Often, clinical studies of expression of a protein in cancer pro-
gression do not correlate because it is important to deﬁne the
nature of the complex as a whole and not an individual protein.
How the total composition of SIN3 complexes is playing a role in
cancer is currently poorly-deﬁned. However, it has been shown
that altering the composition of SIN3 complexes by expressing
BRMS1 or BRMS1 mutants results in 90% suppression of metasta-
sis [30]. The function of these SIN3 complexes is dependent upon
the speciﬁc modiﬁcation of the protein composition and further
emphasizes the need to characterize these complexes as a whole
rather than by individual protein expression.
Gene expression regulated through chromatin remodeling com-
plexes occurs by multiple mechanisms [38]. In simple terms,
although it is much more complicated, histone acetyltransferase
(HAT) containing complexes add acetyl moieties to speciﬁc histone
lysine side chains resulting in an open conformation of DNA
(euchromatin) that is more accessible to transcription factors. His-
tone deacetylase (HDAC) containing complexes remove acetyl moi-
eties from the lysine side chains resulting in a more compact
conformation of DNA (heterochromatin) causing a repression of
transcription. SIN3 (switch-independent 3) is a scaffold that is
well-known for recruitment of HDACs capable of transcriptional
silencing [39,40]. While the majority of current studies with chro-
matin remodeling complexes are focused on HAT or HDAC activity,
these complexes recruit many other protein and DNA modifying
enzymes in addition to deacetylases including glycosyl transfer-
ases and methyl transferases. It is now realized that many of these
enzymatic modiﬁcations are linked and inﬂuence the function of
protein and DNA interacting molecules. The functional speciﬁcity
(i.e., which genes they regulate and, as a result, the phenotypes
that are altered) of these complexes is dictated by their protein
composition and resulting enzyme activity.
HDAC inhibitors are currently in clinical trials since they pro-
mote apoptosis, inhibit invasion and angiogenesis, and cause cell
cycle arrest [41,42]. However, the mechanisms for how HDAC
inhibitors are functioning are not clear. There are currently 11 zinc
containing HDACs and 7 NAD+-dependent HDACs that are found inFig. 1. Pathways regulated by BRMS1. The composition of the SIN3 complex dictates whic
including metastamir (green). The dotted lines indicate either indirect mechanisms or mnearly every cell compartment. They have many diverse functions
since they are not limited to deacetylation of chromatin modifying
histones in the nucleus. It is important to understand how HDACs
and other enzymes are functioning in cancer progression so that
inhibitors can be used appropriately. Matrix metalloproteinase
(MMP) inhibitors were rapidly advanced into clinical trials because
they very effectively inhibited invasion [43]. Unfortunately, clinical
trials with MMP inhibitors failed. The failure was in part due to the
fact that the biology of MMPs was not well understood and their
activities were much more diverse than originally thought. A sim-
ilar situation could occur with the HDAC inhibitors if we fail to
understand the biology and fail to identify proper targets speciﬁ-
cally for metastasis.
Recently Smith et al. showed that select HDAC inhibitors cause
changes to the composition of SIN3 complexes independent of
HDAC inhibition that could lead to signiﬁcant changes in complex
speciﬁcity [34]. This may lead to differential efﬁcacy of HDAC
inhibitors in the treatment of cancer caused by these secondary ef-
fects. Since many of these inhibitors are being tested in clinical tri-
als, it is important to understand how SIN3 complexes are
functioning and how the composition could be affecting enzyme
activity. It is not completely clear how (or even if) BRMS1 alters
HDAC activity although some reports suggest it functions by
recruiting HDAC1 to enhance HDAC activity at speciﬁc locations
[44,45].
The recruitment of HDAC1, and presumably SIN3 complexes,
by BRMS1 leads to inhibition of NFjB activity. BRMS1 has been
shown to recruit HDAC1 to NFjB consensus binding regions using
ChIP assays [44,45]. It has been suggested that HDAC1 leads to H3
deacetylation and reduced binding of p65 at the NFjB site of
speciﬁc promoters. These data imply that BRMS1 is recruited, pos-
sibly via SIN3 complexes, to promoter binding regions where it
inhibits HDAC1 activity leading to deacetylation of p65 and re-
duced transactivation by NFjB. Acetylation is an important regula-
tory mechanism in BRMS1-dependent gene regulation of NFjB
transactivation. The p65 subunit of NFjB is acetylated at lysine
residues by several co-activators including p300, CBP and p/CAF.
K310 is a prominent residue playing a key role in p65
transcriptional regulation. Interestingly, BRMS1 abolishes TNF-
dependent acetylation of p65 on K310 and results in a substantialh genes are regulated. Multiple metastasis associated genes are regulated by BRMS1
ultiple steps not shown. References are provided in the text.
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study, BRMS1 promoted HDAC1 binding to the RelA/p65 subunit of
NFjB where HDAC1 promoted the deacetylation of K310 on p65 at
NFjB binding sites at the promoter regions of cIAP2 and Bﬂ-1/A1
leading to the loss of NFjB-dependent transcriptional activation.
An interesting regulatory feedback loop with microRNA-146a
(miR-146a) has been described for NFjB by Baltimore’s group
[46]. Upon stimulation by LPS, NFjB upregulates miR-146a which
in turn targets the translation of the upstream signaling molecules
IRAK1 and TRAF6 [47]. BRMS1 also upregulates miR-146a and
expression of miR-146a or miR-146b in MDA-MB-231 cells is suf-
ﬁcient to suppress metastasis [48]. It is not clear how BRMS1
upregulates miR-146a since it negatively regulates NFjB although
it could be dependent on the particular environmental stimulus.
Other metastasis-associated microRNAs (metastamir) have been
found to be coordinately regulated by BRMS1 [23]. Molecular path-
ways, including metastamir, regulated by BRMS1 (and presumably
SIN3 complexes) are beginning to be elucidated that signiﬁcantly
impact hallmarks of metastasis [48–51] (Fig. 1). Understanding
the biochemical mechanisms of BRMS1:SIN3:NFjB and how these
molecules are affected by the microenvironment will prove impor-
tant to map key pathological pathways.
3. BRMS1 itself is epigenetically regulated
As described above it has become increasingly clear that epige-
netic modiﬁcations play signiﬁcant roles in the regulation of genes
that drive cancer progression. In fact, the metastasis suppressor
gene nm23 is silenced through promoter methylation and re-
expression following treatment with 5-aza-20-deoxycytidine was
found to cause a decrease in motility of the breast cancer cells
[52]. Breast cancer cell lines with differing tumorigenic and meta-
static potential have been utilized to demonstrate decreased levels
of BRMS1 with increasing aggressiveness [10]. The promoter re-
gion of BRMS1 contains two putative CpG islands leading to the
hypothesis that BRMS1 expression is downregulated by promoter
hypermethylation in advanced stages of cancer. Methylation spe-
ciﬁc PCR (MSP) was used to show that metastatic cells are hyper-
methylated in the distal CpG island (3477 to 2214) of the
BRMS1 promoter and treatment with 5-aza-20-deoxycytidine re-
versed the methylation pattern leading to an increase in BRMS1
expression. However, one must be cautious since the expression le-
vel of BRMS1 in the cell lines tested has not been noted to be di-
rectly proportional to the CpG methylation pattern. At this time
it remains to be determined if there are feedback or feedforward
regulatory loops involving the expression level of BRMS1 and the
interconnectivity of HDAC and methyltransferase activity.
4. Clinical relevance of BRMS1 expression
Promoter hypermethylation of BRMS1 in aggressive tumor cells
might suggest that decreased expression of BRMS1 could serve as a
clinically relevant biomarker. Indeed, a signiﬁcant number of
lymph node metastases in multiple matched patient tissues were
hypermethylated in the distal CpG island (3477 to 2214) [10].
Hypermethylation occurred in 60% of the lymph node metastases
and 45% of the primary tumors, suggesting that an increase in
methylation coincides with cancer development and progression.
A recent study examining circulating tumor cells isolated from
the peripheral blood of operable breast cancer patients identiﬁed
hypermethylation of BRMS1 promoter sequences in patients with
metastases compared to healthy control population [53]. Other
studies found that loss of BRMS1 protein has been correlated with
reduced disease-free survival when patient samples were stratiﬁedby loss of estrogen or progesterone receptor (ER, PR) or expression
of HER2 [54]. Laser capture microdissection is necessary to ensure
purity of the material from a heterogeneous mass and was used to
show that BRMS1 localization shifting from nuclear to cytoplasmic
is associated with highly proliferative ER-negative breast cancers
[55]. More recently, decreased BRMS1 expression was identiﬁed
in metastatic melanomas that is thought to contribute to angiogen-
esis and melanoma progression [56].
Consistent with the protein data, BRMS1 mRNA correlated with
PR and loss of HER2 and loss of BRMS1 mRNA correlated with poor
prognosis [57]. However, not all studies identiﬁed a correlation of
decreased BRMS1 expression with cancer progression. In fact, clin-
ical studies with BRMS1 have been relatively inconsistent with re-
gard to patient survival and likelihood of metastasis. The
inconsistencies are thought to occur mainly because most clinical
studies were performed with measurements of mRNA; and it has
been observed that BRMS1 protein and mRNA do not necessarily
correlate [11]. As techniques are more reﬁned and the target pop-
ulations are more deﬁned, studies with BRMS1 are starting to be
stratiﬁed. Moreover, considering the biochemical mechanisms of
BRMS1 function, it is unlikely that BRMS1 expression alone will
be useful as a prognostic indicator of metastatic potential in cancer
patients. As is the case with the majority of cancer biomarkers,
expression of sets of genes rather than individual genes is more
useful to predict disease progression. This further supports the
need to understand the nature of the protein complexes with
which BRMS1 is interacting and functioning so that clinically rele-
vant biomarkers may be identiﬁed. Future studies may show iden-
tiﬁcation of speciﬁc ‘complexome’ markers associated with cancer
progression and metastasis.
5. Concluding thoughts
It has become increasingly recognized that metastasis is a rele-
vant therapeutic target for cancer patients. Many genes involved in
metastasis are regulated epigenetically and are therefore inﬂu-
enced by their surrounding environments. Understanding how
metastasis regulatory genes are regulated by the microenviron-
ment in which tumor cells ﬁnd themselves will be a signiﬁcant
advancement to the understanding of the mechanisms of metasta-
sis. By deﬁnition, metastasis suppressors are involved in differen-
tial responses to exogenous signals since cells grow in orthotopic
but not ectopic locations. BRMS1 exempliﬁes how expressing and
non-expressing cells respond differentially to the same environ-
mental cues [49]. Further dissection of the mechanisms by which
the metastasis suppressors control cellular responses to signals
(growth factors, matrix molecules, cell adhesion proteins, etc.)
might allow design of new therapeutic strategies targeting metas-
tasis by controlling those interactions.
BRMS1 and SIN3 chromatin remodeling complexes regulate
speciﬁc coding and non-coding genes, depending on the composi-
tion of the complex. These complexes are likely regulated by sig-
nals from the environment surrounding the cell. We hypothesize
that complex composition is likely regulated by signals from the
environments surrounding tumor cells. As metastatic cells travel
to distant sites, they continuously receive different signals from
the changing microenvironments. Depending upon the signal(s)
received, different complexes would be assembled. Then, depend-
ing on the complexes and the genes with which they interact,
pro-survival, pro-apoptotic, or senescence ‘‘operons’’ would be ini-
tiated. BRMS1 may, in fact, alter chromatin remodeling complex
assembly thereby leading to different cellular responses to the
changing microenvironment. Experiments are currently underway
to test these hypotheses and corollaries.
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